Splash

Cystic Fibrosis

Cystic fibrosis is a fatal genetic disease characterized by the build-up of thick, sticky mucus that can damage many of the body's organs.
Splash
Cystic Fibrosis

CF causes repeat and persistent lung infections that result in frequent exacerbations, sudden severe flare-ups of symptoms, and hospitalizations. Patients endure multiple daily medications, frequent hospitalizations and, ultimately, selected patients have lung transplants.

The quality of life for CF patients is compromised as a result of spending significant time on self-care every day and frequent medical visits and hospitalizations. The US and European regulatory authorities consider CF to be a rare, or orphan, disease and provide incentives to encourage development of effective new treatments.

46

Years

Median life expectancy for CF patients is 46 years

~105,000

People

Diagnosed with CF worldwide

~1,000

CF

New cases diagnosed each year

According to the Cystic Fibrosis Foundation, approximately 40,000 people in the US and an estimated 105,000 people worldwide have been diagnosed with CF across 94 countries.

Ensifentrine has been shown to activate the Cystic Fibrosis Transmembrane Conductance Regulator, which is beneficial in reducing mucous viscosity and improving mucociliary clearance. This suggests ensifentrine has potential as a therapy for CF.

Splash

© Verona Pharma plc 2022. All rights reserved